Tagrisso 80 mg is a prescription targeted anticancer medicine containing osimertinib. It is used in specific clinical settings involving non-small cell lung cancer (NSCLC) associated with certain epidermal growth factor receptor (EGFR) mutations. The medicine works by inhibiting susceptible mutant EGFR proteins involved in the growth and survival of cancer cells.
This guide provides an overview of Tagrisso 80 mg, including its active ingredient, therapeutic uses, mechanism of action, administration, potential adverse reactions, precautions and the importance of medical supervision. It is intended to support informed conversations between patients and healthcare professionals rather than replace individualized medical advice.
What Is Tagrisso 80 mg?
Tagrisso is the brand name associated with osimertinib, an oral medicine classified as an EGFR tyrosine kinase inhibitor. The 80 mg strength identifies the amount of osimertinib in each tablet of the product described here.
Osimertinib is designed to inhibit certain altered forms of EGFR that can contribute to the development and progression of lung cancer. Its targeted action makes it different from conventional cytotoxic chemotherapy, although it can still cause significant adverse reactions.
Tagrisso is not suitable for every person with lung cancer. Its use depends on the specific clinical indication, molecular test results, disease stage, prior treatment and other individual factors.
What Is Osimertinib?
Osimertinib is the active pharmaceutical ingredient in Tagrisso. It blocks the tyrosine kinase activity of susceptible mutant EGFR proteins.
EGFR is involved in cellular signaling that regulates growth and survival. Certain mutations can cause abnormal signaling that contributes to cancer-cell proliferation. By inhibiting these signals, osimertinib can help control the disease in appropriately selected patients.
The response to treatment varies. Some patients may experience a substantial clinical benefit, while others may have a limited response or develop resistance over time. No individual outcome can be guaranteed.
What Is Tagrisso 80 mg Used For?
Tagrisso is authorized for specific treatment settings involving EGFR-mutated NSCLC. Depending on the applicable national authorization, these may include:
- Adjuvant treatment after complete surgical removal of a tumor in eligible patients with specified EGFR mutations.
- Treatment after definitive chemoradiation for selected patients with unresectable stage III disease and an appropriate EGFR mutation.
- First-line treatment of certain patients with locally advanced or metastatic EGFR-mutated NSCLC.
- Treatment of selected patients with EGFR T790M mutation-positive advanced NSCLC after progression on or following previous EGFR-targeted therapy.
- Combination treatment with pemetrexed and platinum-based chemotherapy in certain approved first-line settings.
The exact indications, mutation requirements and eligibility criteria may differ by jurisdiction. The treating oncologist should confirm the indication using the current prescribing information and the patient’s diagnostic results.
Why Is EGFR Testing Important?
Molecular testing helps identify genetic alterations that may influence cancer treatment. For osimertinib, the relevant EGFR mutation is an important factor in determining whether treatment is appropriate.
The oncology team reviews the molecular test report alongside the pathology findings, cancer stage, previous therapies and overall health of the patient.
Not every EGFR mutation has the same treatment implications. Patients should ask their healthcare professional to explain their specific mutation and how it relates to the proposed treatment.
A diagnosis of NSCLC alone does not establish eligibility for Tagrisso, and patients should not begin treatment based solely on online information or another person’s experience.
How Does Tagrisso Work?
Osimertinib inhibits susceptible mutant EGFR proteins and interferes with signaling pathways involved in cancer-cell growth and survival.
Its activity includes inhibition of certain activating EGFR mutations, such as exon 19 deletions and exon 21 L858R substitutions. It also has activity against the T790M resistance mutation in relevant clinical settings.
By reducing abnormal signaling, osimertinib may help control cancer in patients whose tumors are susceptible to the medicine. However, cancer cells may develop resistance mechanisms, and treatment effectiveness can change over time.
The treating clinician evaluates response through appropriate clinical assessments and investigations rather than relying only on how the patient feels.
Dosage and Administration
The usual adult regimen described in official prescribing information for applicable indications is 80 mg orally once daily. The appropriate regimen must be determined by the prescribing clinician.
Patients should follow the dose and schedule written on their prescription and the instructions supplied with their specific product.
Important administration considerations include:
- Take the medicine according to the prescribed schedule.
- Follow the current patient leaflet for food and administration instructions.
- Do not take a double dose to compensate for a missed dose.
- If vomiting occurs after taking a dose, follow the patient leaflet or seek professional advice instead of automatically repeating it.
- Do not independently increase, reduce or discontinue treatment.
- Ask a pharmacist for guidance if the tablet is difficult to swallow or the administration instructions are unclear.
Dose interruption or modification may be necessary in certain clinical circumstances, including some adverse reactions. Such decisions should be made by the treating healthcare professional.
Benefits and Treatment Objectives
The potential benefits of Tagrisso depend on the treatment setting.
In an adjuvant setting, treatment may reduce the risk of cancer recurrence in eligible patients after surgery. Following definitive chemoradiation, it may help control disease in appropriately selected patients with unresectable stage III NSCLC. In advanced disease, treatment may help control tumor growth and delay disease progression.
These objectives are not identical, and the expected benefits should be discussed in relation to the patient’s individual diagnosis.
Treatment response varies, and the medicine cannot guarantee a cure, prevent every recurrence or eliminate the possibility of disease progression. The oncology team can explain the expected goals, limitations and alternatives.
Common Side Effects
Commonly reported adverse reactions include:
- Diarrhea.
- Skin rash.
- Dry skin.
- Nail changes and inflammation around the nails.
- Inflammation of the mouth.
Symptoms vary in severity and duration. Persistent diarrhea may lead to dehydration, while skin reactions or mouth sores can affect comfort and daily activities.
Patients should report symptoms that persist, worsen or interfere with eating, drinking, sleeping or normal activities. A healthcare professional can assess the problem and recommend suitable management.
Patients should not start additional medicines or supplements for side effects without checking whether they are appropriate during treatment.
Serious Warnings and Precautions
Osimertinib can cause serious adverse reactions. Important risks include interstitial lung disease or pneumonitis, QT prolongation, cardiomyopathy, keratitis and aplastic anemia.
Pulmonary toxicity: New or worsening shortness of breath, persistent cough or other unexplained respiratory symptoms require prompt medical assessment.
Heart rhythm changes: Fainting, palpitations or a rapid or irregular heartbeat should be evaluated promptly.
Heart muscle problems: New or worsening breathlessness, swelling or unexplained fatigue may require assessment for changes in heart function.
Eye problems: Significant eye pain, redness or changes in vision should not be ignored.
Blood-related complications: Unusual bruising, bleeding, marked weakness or unusual infections should be reported to a healthcare professional.
Severe or rapidly worsening symptoms may require emergency medical assistance. Patients should not delay care while searching for online explanations.
Drug Interactions
Before starting Tagrisso, patients should tell their healthcare team about all prescription medicines, nonprescription products, vitamins, supplements and herbal remedies they use.
Some combinations may create additional safety risks, particularly where medicines affect heart rhythm or have overlapping adverse effects. The significance of an interaction depends on the specific products and the patient’s medical circumstances.
Patients should not independently discontinue other medicines or begin new supplements. A pharmacist or oncologist can assess potential interactions and recommend appropriate precautions.
Pregnancy and Breastfeeding
Osimertinib may cause fetal harm. Patients who are pregnant, planning pregnancy or who think they may be pregnant should contact their healthcare team promptly.
The prescribing clinician should explain the applicable pregnancy-prevention precautions and contraception requirements using the current official product information.
Breastfeeding also requires medical advice because the medicine may pose risks to a nursing infant. Patients should discuss the relevant precautions before starting treatment or changing their feeding plans.
Monitoring During Treatment
Regular monitoring helps the oncology team evaluate treatment response, identify adverse reactions and determine whether the prescribed regimen remains appropriate.
Depending on the indication and individual risk factors, monitoring may include clinical assessments, imaging, laboratory tests, electrocardiography or assessment of heart function.
Patients should attend scheduled appointments, follow the monitoring plan and report new symptoms promptly. They should also inform their healthcare team about missed doses, newly prescribed medicines and changes in their health.
Storage and Product Verification
Store Tagrisso according to the instructions provided with the specific product. Check the expiry date and keep the medicine out of the reach of children.
Review the product name, active ingredient, strength, batch or lot number, expiry date and company details on the packaging. Obtain prescription medicines through legitimate supply channels.
A package photograph, printed logo, barcode or QR code alone cannot conclusively establish authenticity. If the package appears tampered with, damaged, expired or inconsistent with the prescription, consult a pharmacist before using it.
Frequently Asked Questions About Tagrisso 80 mg
Is Tagrisso 80 mg chemotherapy?
Tagrisso is a targeted EGFR tyrosine kinase inhibitor rather than conventional cytotoxic chemotherapy. However, it may be combined with chemotherapy in certain approved treatment settings.
Can everyone with lung cancer take Tagrisso?
No. Treatment is intended for specific clinical indications involving particular EGFR mutations. Eligibility must be assessed by a qualified oncology professional.
How often is Tagrisso usually taken?
The usual adult regimen described in official prescribing information for applicable indications is 80 mg orally once daily. Patients must follow their individual prescription.
Can Tagrisso cause serious side effects?
Yes. Serious risks include pulmonary toxicity, QT prolongation, cardiomyopathy, keratitis and aplastic anemia. Patients should understand the warning symptoms and monitoring plan.
What should I do if I miss a dose?
Follow the missed-dose instructions in the current patient leaflet. Do not take an extra or double dose to compensate. Ask a pharmacist or oncology professional if the correct next step is unclear.
Should I stop treatment if I feel better?
Do not stop treatment independently. The appropriate duration depends on the indication, treatment response, tolerability and the prescribing clinician’s plan.
Conclusion
Tagrisso 80 mg contains osimertinib, a targeted anticancer medicine used in specific EGFR-mutated NSCLC treatment settings. Its use requires appropriate molecular testing, individualized prescribing, an understanding of potential adverse reactions and ongoing medical supervision.
Patients should follow their prescribed regimen, attend monitoring appointments, disclose other medicines and report concerning symptoms promptly. The current official prescribing information and advice from the treating healthcare professional should guide all treatment decisions.
Medical Disclaimer: This page is provided for general educational purposes only. It does not replace professional medical advice, diagnosis, treatment or current official prescribing information. Approved indications and requirements may vary by jurisdiction. Tagrisso should be used only under the supervision of a qualified healthcare professional. Seek urgent medical assistance for severe or rapidly worsening symptoms.